The national pharmaceutical company Zydus Cadila obtained authorization from the Committee of Experts in the Field (SEC) to conduct clinical trials of its monoclonal antibody (mAb) cocktail for the treatment of Covid-19, ANI reported.
“The SEC is providing advice for the phase 1 and 2 clinical trials of the biologic treatment ZRC-3308 of Zydus Cadila, a cocktail of two neutralizing monoclonal antibodies (mAb) of SARS-CoV-2 that would possibly emerge as one of the main remedies for mild Covid-19. ,” said a source quoted through the news agency.
ZRC-3308 is a cocktail of two anti-SARS-CoV-2 monoclonal antibodies. The monoclonal antibodies in ZRC-3308 were designed in particular to provide protection for a much longer period of time than the recently approved products, the company claims.
As a result of this trend, Zydus is the only Indian company to get the green light from the Central Organization for Standard Control of Drugs (SEC) to test its antibody cocktail.
At the time of the authorization request, the company had stated that the cocktail could be one of the main treatments against mild Covid-19.
“Neutralizing monoclonal antibody treatments targeting the SARS-CoV-2 spike protein gained emergency use authorization in the treatment of mild Covid-19 in the United States, Europe, and IndiaArray because they particularly reduced viral load in patients. ” mild illnesses and their hospitalization rate. ”says Zydus.
Currently, some hospitals administer a cocktail of two fast-acting antibodies: casirivimab and imdevimab. A batch of the Roche Antibody Cocktail drug arrived in the country on May 24. The cost of a single antibody cocktail costs ₹59,750.
Another antibody cocktail that gained approval comes from Eli Lilly and Company. The company recently announced that it obtained approval to limit emergency use of its antibodies, bamlanivimab 700 mg and etesevimab 1,400 mg, in India for the treatment of patients with mild to moderate coronavirus disease 2019.
Get the latest news, events, and business updates on Live Mint. Download the Mint News app for market updates.
Download the Mint app and premium items
Sign in to our to save your favorites. It will only be a matter of a moment.